The Defence Analysis and Improvement Organisation (DRDO), which developed 2-Deoxy-D-Glucose (2-DG), a drug used for therapy of COVID-19 sufferers, has referred to as for Expression of Curiosity (EoI) to switch the expertise to Indian pharmaceutical industries for manufacturing.
2-DG was developed by the Institute of Nuclear Medication and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’s Laboratories. Medical trial outcomes have proven that this molecule helps in sooner restoration of hospitalised sufferers and reduces supplemental oxygen dependence. Larger proportion of sufferers handled with 2-DG confirmed RT-PCR damaging conversion in COVID sufferers.
In keeping with the EoI doc, functions ought to be submitted earlier than June 17 via e mail.
“The EoI submitted by industries can be scrutinised by a Technical Evaluation Committee (TAC). Solely as much as 15 industries can be given ToT on their capabilities, technical hand holding functionality of DRDO and on First Come First Served Foundation,” it stated.
The bidders ought to have a Drug license to fabricate Energetic Pharmaceutical Ingredient (API) from Drug Licensing Authorities and WHO GMP (Good manufacturing Practices) certification amongst others.
Laboratory synthesis course of for 2-DG has been developed utilizing D-Glucose as beginning materials. The synthesis course of consists of conversion of D-Glucose to 2-DG via 5 chemical response steps adopted by purification.
The method has been established at batch scale (100g) and pilot plant scale (500g) and essential patents have been filed by DRDO on this regard, the Defence physique stated.